Person:
Pedrero Muñoz, María

Profile Picture
First Name
María
Last Name
Pedrero Muñoz
URI
https://hdl.handle.net/20.500.14352/76134
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Ciencias Químicas
Department
Química Analítica
Area
Química Analítica
Identifiers
UCM identifierORCIDScopus Author IDWeb of Science ResearcherIDDialnet IDGoogle Scholar ID

Filters

1989 - 198912020 - 20241
Reset filters

Settings

Has files: false ×

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    On regular and stable ruled surfaces in P3
    (Algebraic curves and projective geometry, 1989) Arrondo Esteban, Enrique; Pedrero Muñoz, María; Sols, Ignacio
  • No Thumbnail Available
    Item
    Angiogenesis inhibitor or aggressiveness marker? The function of endostatin in cancer through electrochemical biosensing
    (Bioelectrochemistry, 2024) Tejerina Miranda, Sandra; Pedrero Muñoz, María; Blázquez García, Marina; Serafín González-Carrato, Verónica; Montero Calle, Ana; Garranzo Asensio, María; Reviejo García, Ángel Julio; Pingarrón Carrazón, José Manuel; Barderas Manchado, Rodrigo; Campuzano Ruiz, Susana
    This work reports the first electrochemical bioplatform developed for the determination of human endostatin (HE), a biomarker with recognized antiangiogenic potential whose elevated circulating levels have also been associated with the development of aggressive cancers. The developed electroanalytical biotool combines the benefits of using magnetic microparticles for the implementation of sandwich immunoassays and amperometric transduction on disposable carbon electrodes. A limit of detection (LOD) of 34.1 pg mL−1 for HE standards and a selectivity suitable for its foray into the clinical oncology area, are demonstrated. The determination of HE in clinical samples such as lysates and secretomes of colorectal cancer (CRC) cells, plasma, and tissue samples from patients with CRC in different stages, has been faced with satisfactory results showing the ability for discriminating the metastatic capabilities of cells and for identifying and staging CRC patients. The developed bioplatform allows precise quantitative determinations, requiring minimal pre-treatments and sample amounts in only 75 min. In addition, due to the instrumentation and the type of substrates used in the detection step, the biotool is compatible with implementation in multiplexed and/or point-of-need devices, features in which this bioplatform is advantageous with respect to the enzyme linked immunosorbent assay (ELISA) or immunoblotting technologies.